A 73-Year-Old Woman With Differentiated Thyroid Cancer
The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
Elinzanetant Gets Priority Review for VMS From Breast Cancer Endocrine Therapy
4
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
5